Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery

References

• McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846–4861.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. The Lancet. 2011;378(9791):607–620. Aug
   PubMed Web of Science ®Google Scholar
• Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801–810.
   PubMed Web of Science ®Google Scholar
• Tempero MA, Malafa MP, Chiorean EG, et al. Pancreatic adenocarcinoma, version 1.2019. J Natl Compr Cancer Netw JNCCN. 2019;17(3):202–210.
   PubMed Web of Science ®Google Scholar
• Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155(6):977–988.
   PubMed Web of Science ®Google Scholar
• Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(8):1028–1061.
   PubMed Web of Science ®Google Scholar
• Huguet F, Mornex F, Orthuon A. Radiation therapy of pancreatic cancer. Cancer Radiother. 2016;20(Suppl):S169–S173.
   PubMedGoogle Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl. 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• Sanjay P, Takaori K, Govil S, et al. 'Artery-first' approaches to pancreatoduodenectomy. Br J Surg. 2012;99(8):1027–1035.
   PubMed Web of Science ®Google Scholar
• Adsay NV, Basturk O, Saka B, et al. Whipple made simple for surgical pathologists: orientation, dissection, and sampling of pancreaticoduodenectomy specimens for a more practical and accurate evaluation of pancreatic, distal common bile duct, and ampullary tumors. Am J Surg Pathol. 2014;38(4):480–493.
   PubMed Web of Science ®Google Scholar
• Tol JAMG, Gouma DJ, Bassi C, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2014;156(3):591–600.
   PubMed Web of Science ®Google Scholar
• Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–213.
   PubMed Web of Science ®Google Scholar
• RCPA – Pancreas resection [Internet]. [cited 2019 Sep 10]. Available from: https://www.rcpa.edu.au/Manuals/Macroscopic-Cut-Up-Manual/Gastrointestinal/Pancreas/Pancreas-resection.
   Google Scholar
• TNM classification of malignant tumours – NLM Catalog – NCBI [Internet]. [cited 2020 Jan 5]. Available from: https://www.ncbi.nlm.nih.gov/nlmcatalog/101511218.
   Google Scholar
• Homepage [Internet]. [cited 2019. Dec 27]. Available from: https://www.rcpath.org/.
   Google Scholar
• He J, Blair AB, Groot VP, et al. Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer? Ann Surg. 2018;268(1):1–8.
   PubMed Web of Science ®Google Scholar
• Pietrasz D, Marthey L, Wagner M, et al. Pathologic major response after FOLFIRINOX is prognostic for patients secondary resected for borderline or locally advanced pancreatic adenocarcinoma: an AGEO-FRENCH, prospective, multicentric cohort. Ann Surg Oncol. 2015;22(S3):1196–1205.
   PubMed Web of Science ®Google Scholar
• Venables WN, Ripley BD. 2002. Modern applied statistics (Fourth S, editor). New York: Springer.
   Google Scholar
• Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–2406.
   PubMed Web of Science ®Google Scholar
• Katz MHG, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg. 2016;151(8):e161137
   PubMed Web of Science ®Google Scholar
• Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(7):963–969.
   PubMed Web of Science ®Google Scholar
• American Joint Committee on Cancer. Edge SB, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. 648. p.
   Google Scholar
• Verbeke CS, Menon KV. Redefining resection margin status in pancreatic cancer. HPB (Oxford)). 2009;11(4):282–289.
   PubMed Web of Science ®Google Scholar
• Delpero JR, Bachellier P, Regenet N, et al. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB. 2014;16(1):20–33.
   PubMed Web of Science ®Google Scholar
• Chandrasegaram MD, Goldstein D, Simes J, et al. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br J Surg. 2015;102(12):1459–1472.
   PubMed Web of Science ®Google Scholar
• Hartwig W, Hackert T, Hinz U, et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg. 2011;254(2):311–319.
   PubMed Web of Science ®Google Scholar
• Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2–11.
   PubMed Web of Science ®Google Scholar
• Pietrasz D, Turrini O, Vendrely V, et al. How does chemoradiotherapy following induction FOLFIRINOX improve the results in resected borderline or locally advanced pancreatic adenocarcinoma? An AGEO-FRENCH multicentric cohort. Ann Surg Oncol. 2019;26(1):109–117.
   PubMed Web of Science ®Google Scholar
• Elshaer M, Gravante G, Kosmin M, et al. A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma. Ann R Coll Surg Engl. 2017;99(2):101–106.
   PubMed Web of Science ®Google Scholar
• Oba A, Ho F, Bao QR, et al. Neoadjuvant treatment in pancreatic cancer. Front Oncol. 2020;10:245.
   PubMed Web of Science ®Google Scholar
• Cools KS, Sanoff HK, Kim HJ, et al. Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy. J Surg Oncol. 2018;118(3):455–462.
   PubMed Web of Science ®Google Scholar
• Merkow RP, Bilimoria KY, Tomlinson JS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260(2):372–377.
   PubMed Web of Science ®Google Scholar
• Zhan H-X, Xu J-W, Wu D, et al. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Cancer Med. 2017;6(6):1201–1219. Jun
   PubMed Web of Science ®Google Scholar
• Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer: upfront surgery versus neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946–958.
   PubMed Web of Science ®Google Scholar
• Jang J-Y, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268(2):215–222.
   PubMed Web of Science ®Google Scholar
• Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–1773.
   PubMed Web of Science ®Google Scholar
• Tang K, Lu W, Qin W, et al. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. Pancreatology. 2016;16(1):28–37. Jan
   PubMed Web of Science ®Google Scholar
• Tummers WS, Groen JV, Sibinga Mulder BG, et al. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Br J Surg. 2019;106(8):1055–1065.
   PubMed Web of Science ®Google Scholar
• Institut de Cancérologie de Lorraine. Two arm, prospective, multicenter randomized phase II trial of neoadjuvant modified FOLFIRINOX regimen, with or without preoperative concomitant chemoradiotherapy in patients with borderline resectable pancreatic carcinoma [Internet]. clinicaltrials.gov; 2020. [cited 2020 Aug 23]. Report No.: NCT02676349. Available from: https://clinicaltrials.gov/ct2/show/NCT02676349.
   Google Scholar
• Truty MJ, Kendrick ML, Nagorney DM, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer. Ann Surg. 2021;273(2):341–349.
   PubMed Web of Science ®Google Scholar